Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Interest Expenses (2020 - 2023)

Relay Therapeutics (RLAY) has disclosed Interest Expenses for 4 consecutive years, with $3000.0 as the latest value for Q1 2023.

  • On a quarterly basis, Interest Expenses fell 85.71% to $3000.0 in Q1 2023 year-over-year; TTM through Dec 2023 was $3000.0, a 85.71% decrease, with the full-year FY2020 number at $16000.0, down 72.41% from a year prior.
  • Interest Expenses was $3000.0 for Q1 2023 at Relay Therapeutics, down from $21000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $21000.0 in Q1 2022 to a low of $3000.0 in Q1 2023.
  • A 4-year average of $8400.0 and a median of $5000.0 in 2020 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: surged 320.0% in 2022, then plummeted 85.71% in 2023.
  • Relay Therapeutics' Interest Expenses stood at $8000.0 in 2020, then tumbled by 37.5% to $5000.0 in 2021, then soared by 320.0% to $21000.0 in 2022, then plummeted by 85.71% to $3000.0 in 2023.
  • Per Business Quant, the three most recent readings for RLAY's Interest Expenses are $3000.0 (Q1 2023), $21000.0 (Q1 2022), and $5000.0 (Q1 2021).